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Abstract
Background: Increased transcription of oncogenes like the epidermal growth factor receptor (EGFR) is frequently
caused by amplification of the whole gene or at least of regulatory sequences. Aim of this study was to pinpoint
mechanistic parameters occurring during egfr copy number gains leading to a stable EGFR overexpression and
high sensitivity to extracellular signalling. A deeper understanding of those marker events might improve early
diagnosis of cancer in suspect lesions, early detection of cancer progression and the prediction of egfr targeted
therapies.
Methods: The basal-like/stemness type breast cancer cell line subpopulation MDA-MB-468 CD44
high/CD24
-/low,
carrying high egfr amplifications, was chosen as a model system in this study. Subclones of the heterogeneous cell
line expressing low and high EGF receptor densities were isolated by cell sorting. Genomic profiling was carried
out for these by means of SNP array profiling, qPCR and FISH. Cell cycle analysis was performed using the BrdU
quenching technique.
Results: Low and high EGFR expressing MDA-MB-468 CD44
+/CD24
-/low subpopulations separated by cell sorting
showed intermediate and high copy numbers of egfr, respectively. However, during cell culture an increase solely
for egfr gene copy numbers in the intermediate subpopulation occurred. This shift was based on the formation of
new cells which regained egfr gene copies. By two parametric cell cycle analysis clonal effects mediated through
growth advantage of cells bearing higher egfr gene copy numbers could most likely be excluded for being the
driving force. Subsequently, the detection of a fragile site distal to the egfr gene, sustaining uncapped telomere-
less chromosomal ends, the ladder-like structure of the intrachromosomal egfr amplification and a broader range of
egfr copy numbers support the assumption that dynamic chromosomal rearrangements, like breakage-fusion-
bridge-cycles other than proliferation drive the gain of egfr copies.
Conclusion: Progressive genome modulation in the CD44
+/CD24
-/low subpopulation of the breast cancer cell
line MDA-MB-468 leads to different coexisting subclones. In isolated low-copy cells asymmetric chromosomal
segregation leads to new cells with regained solely egfr gene copies. Furthermore, egfr regain resulted in
enhanced signal transduction of the MAP-kinase and PI3-kinase pathway. We show here for the first time a
dynamic copy number regain in basal-like/stemness cell type breast cancer subpopulations which might explain
genetic heterogeneity. Moreover, this process might also be involved in adaptive growth factor receptor
intracellular signaling which support survival and migration during cancer development and progression.
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Increased transcription of (proto-) oncogenes is fre-
quently caused by amplification. This has already been
shown for numerous genes for example in lung [1], pan-
creatic [2], brain [3] and breast cancer [4]. It is still
under debate if this process is the dominant cancer
cause and promoter of cancer progression or if distinct
DNA sequence mutations have to lead the way. Clonal
selection during cancer development may lead to a
dominant cancer cell subpopulation with distinct chro-
mosomal alterations. But, in most cases a heterogeneous
cell population can be found within one tumour. Here,
the non-ambiguous relationship between the genotype
of distinct loci and the phenotype is physiological a rare
event and therefore, highly selective in cancer. Although,
contemporary genetics has shown that quantitative trait
loci exist [5], it is unlikely that the gene dosage sensitiv-
ity for a single locus significantly changes the phenotype
of normal somatic cells. However, specific gene families
e.g. involved in essential signal transduction systems
show such dosage sensitivity in cancer. The most promi-
nent example for those genes are the HER receptor
family, most prominent EGFR, which induce signal
transduction for survival, proliferation and migration.
Patients suffering from carcinoma associated with gene
amplification and overexpression of EGFR tend to have
more aggressive diseases. EGFR overexpression has been
associated with poor prognosis in human breast cancer
[6,7] and failure of endocrine therapy in breast cancer as
well [8,9].
Although, overexpression of EGFR may be regulated
on the transcriptional level, in many cases aberrant acti-
vation of EGFR is mediated primarily by chromosomal
changes generating increased egfr gene copy numbers.
Amplifications of the egfr gene can be detected in vivo
sometimes as double minutes but in most cases forma-
tion of homologous staining regions (HSR) as ladder
like amplification structures can be observed. This was
seen frequently in glioblastoma multiforme where
amplification and overexpression of the egfr gene occurs
in about 40% of the cases [10].
However, cell culture models reflecting these charac-
teristics are fairly seldom. Even more, primary tumours
taken into cell culture often loose their egfr gene ampli-
fication and by this the originally displayed heterogene-
ity [11,12]. Among the remaining few cell culture
models with conserved egfr amplifications and overex-
pression of the receptor the breast cancer cell line
MDA-MB-468 as well as the subclone MDA-MB-468
CD44+/CD24
-/LOW reflect best the above described find-
ings. For both clones, not only a intrachromosomal high
copy egfr gene amplification can be found which is
based upon one abnormal chromosome 7 but also a
heterogeneous cell population which differs in the grade
of this amplification. Furthermore, the grade of amplifi-
cation reflects the expression of the receptor. Far
beyond these genetic properties MDA-MB-468 CD44
+/CD24
-/LOW is a valuable model for studies in breast
cancer progression because it is likely to represent a
basal-like/stemness cell phenotype of breast cancer.
Besides the expression of cytokeratin 5/6 the subline
investigated here consisted of CD44
+/CD24
-/low cells
which supports the hypothesis that it has the intrinsic
capability for asymmetric cell division [13,14]. We there-
fore choose this cell line model to study the underlying
mechanism as well as the kinetics of isolated egfr gene
copy number variation.
Methods
Cell culture
MDA-MB-468 CD44+/CD24 -/LOW were described
elsewhere [13]. In contrary to the standard culture con-
ditions (aMEM, 10% FBS) cells were cultured in Dul-
becco’s Modified Eagle Medium (DMEM) supplemented
with nonessential amino acids (GIBCO/BRL), 5% fetal
calf serum and antibiotics in a humidified 5% CO2 incu-
bator at 37°C.
Immunostaining
For the cell surface antigen staining, single cell suspen-
sions were prepared by detaching 1-3 × 10
6 cells with
0.5 mM EDTA in phosphate buffered saline (PBS) for 5
min and washed twice with PBS at room temperature.
Blocking was performed with 1% BSA in PBS for 30
min followed by incubation for 1 h on ice with the
FITC labeled primary mouse monoclonal antibody
EGFR 528 (Santa Cruz Biotechnology) targeting an
extracellular epitope of EGFR. Two additional washing
steps were followed and cells were resuspended in PBS.
Flow cytometry
Fluorescence Activated Cell Sorting (FACS)
Cell fluorescence signals were determined immediately
after staining using a FACSVantage SE flow cytometer
(Becton Dickinson) equipped with an argon laser emis-
sion of 488 nm. FITC was identified by using a 530
band pass filter. The analysis was performed using
CELLQUEST software (Becton Dickinson). A primary
gate based on physical parameters (forward and side
light scatter, FSC and SSC, respectively) was set to
exclude debris and cell aggregates. The background level
was estimated by omitting the primary antibody. For
isolation of subpopulations two additional gates were set
discriminating clearly a high- from a low-level EGFR-
expressing population. Either isolated cells were directly
used for FISH, quantitative real-time PCR and SNP
Agelopoulos et al. BMC Cancer 2010, 10:78
http://www.biomedcentral.com/1471-2407/10/78
Page 2 of 10arrays respectively, or after adherence and cell culture as
described above.
Particle Analyzing System (PAS)
For flow cytometric analysis a PAS III flow cytometer
(Partec, Muenster, Germany) equipped with a 488-nm
argon ion laser was used. Data acquisition and evalua-
tion were done with FlowMax software (Quantum Ana-
lysis, Münster, Germany).
Genomic profiling
High resolution SNP analysis
DNA was extracted from MDA 468 high and low copy
number cells and each was typed twice using GenChip®
Human Mapping 500 k arrays (Affymetrix®). The inten-
sity values were calculated as means of the both corre-
sponding arrays. The data set was normalized by the
dChip software which uses the invariant set normaliza-
tion and a hidden Markov model [15]. The SNP inten-
sity values were calculated by referencing the means of
each pair of repeated measurement to the means of a
second pair repeated measurements (pairs: EGFR low vs.
EGFR high). Regions of elevated or reduced copy num-
ber were calculated by DNAcopy package 1.10.0 and
GLAD to identify and visualize change-points [16].
Quantitative real-time PCR (5’ nuclease assay)
Quantitative real-time PCR for the egfr gene was carried
out as previously described [17]. PCR reactions (40 cycles;
15 seconds denaturation at 95°C; 1 minute primer anneal-
ing and extension at 60°C) were performed for egfr as well
as for SOD2 at least in triplicates. DNA concentrations
were normalized to the single copy gene SOD2. Amplifica-
tion of the egfr gene was measured in MDA-MB-468
CD44+/CD24 -/LOW populations directly after isolation
according to their EGFR-expression by FACS as well as in
populations cultured for up to 92 days after sorting.
Fluorescence in situ hybridization (FISH) on metaphase and
interphase nuclei
Dividing cells were blocked in metaphase by addition of
colcimide for at least 4 h before harvest. Interphase
nuclei preparation was performed directly from these
cultures. Standard cytogenetic techniques were used for
harvesting and slide preparation.
FISH was carried out as previously described [17]. In
brief, probes were denatured for 5 min at 70°C in 70%
formamid-0.6×SSC. Hybridization to the metaphase as
well as interphase spreads was carried out overnight at
37°C in a 50% formamid-1×SSC-10% dextran sulfate
solution in the presence of Cot-1-DNA (Gibco) and
HPL-DNA (Sigma). Post-hybridization washes were per-
formed at 45°C in 50% formamide-2×SSC. The chromo-
somes/nuclei were counterstained with DAPI, and
images were captured with an Olympus BX61 micro-
scope connected with a digital camera system DP50
(Hamburg, Germany).
Cell cycle/Proliferation analysis
Progression of cell cycle phases was determined using
the BrdU quenching technique according to the proto-
col of Böhmer and Ellwart [18]. Briefly, prior the above
described sorting procedure cells were incubated for
18 h in 10 ml culture medium in the presence of 24 μg
BrdU and 100 μg desoxycytidin. After cell sorting the
cellular DNA of the subpopulations was stained for 1 h
with 1.2 μg Hoechst 33342 and 1.5 μg ethidium bromide
per milliliter Tris/NaCl buffer containing 0.1% Nonidet
P40 and 0.2% bovine serum albumine (BSA).
For flow cytometric analysis a PAS III flow cytometer
(Partec, Muenster, Germany) equipped with a mercury
arc lamp for UV excitation was used. Ethidium bromide
excitation was measured at 620 nm and Hoechst 33342
fluorescence at 455 nm. Data acquisition and evaluation
were done with FlowMax software (Quantum Analysis,
Muenster, Germany).
SDS-PAGE and western blot analysis
Protein separation was done using 10% polyacrylamide
separation gels. Samples were diluted in SDS-sample buf-
fer, heat denatured at 95°C for 5 min and loaded onto the
gel under the following running conditions: 84 V for 1 h
and 130 V until the dye front reached the edge of the gel.
The molecular size standard was the peqGOLD protein-
marker V (Peqlab, Erlangen, Germany). For Western Blot
analysis separated samples (20 μg of protein) were trans-
ferred to a PDVF membrane under semi-dry conditions.
Alpha-Tubulin, Akt, phospho-Akt (Ser473), EGFR, Erk,
phospho-Erk (Thr202/Tyr204), CD44, CD24 and cytoker-
atin 5 were detected using the following primary antibo-
dies: rabbit anti-human alpha-tubulin polyclonal Ig (Cell
Signaling, Danvers, MA, USA), rabbit anti-human Akt
polyclonal Ig (Cell Signaling), rabbit anti-human phospho-
Akt polyclonal Ig (Cell Signaling), rabbit anti-human
EGFR polyclonal Ig (Santa Cruz Biotechnology, Santa
Cruz, USA), rabbit anti-human p44/42 MAP-Kinase poly-
clonal Ig (Cell Signaling), rabbit anti-human phospho-p44/
42 MAP-Kinase polyclonal Ig (Cell Signaling), rabbit anti-
human CD44 monoclonal Ig (abcam, Cambridge, United
Kingdom) and mouse anti-human CD24 monoclonal Ig
(dianova, Hamburg, Germany). Bands were visualized
using the enhanced chemiluminescence detection system
and X-ray films (both GE Healthcare, Uppsala, Sweden) in
accordance to the manufacturer’s instructions. X-ray films
were digitized (GS-700 imaging densitometer, Bio-Rad)
and processed (Quantity one, Bio-Rad). For quantitative
analysis of the Erk and phospho Erk signal intensities, the
signals of Erk1 and Erk2 were combined. For each Wes-
tern Blot the signal intensities were normalized to the
MDA-MB-468 CD44+/CD24 -/LOW high cultured in
DMEM supplemented with 5% FCS (lane 1). Each reaction
was performed in biological triplicates.
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Using cell sorting by flow cytometry a low and a high
EGFR expressing MDA-MB-468 CD44
+/CD24
-/low sub-
population was separated and confirmed by reanalysis
(Fig 1, insert Western Blott for CD44 and CD24). In
both populations standard CGH and SNP array analysis
revealed a gain of chromosome 7p11-14, the chromoso-
mal localization of egfr.A l lS N Pi nt h ec h r o m o s o m a l
segment between 54,498,075 and 57,357,367 which
spans the gene locus of egfr showed an increased copy
number. But, the SNP within this homogeneous seg-
ment in term of copy number showed a significant dif-
ferent gene copy number between high and low
expressing cells. No other statistically significant differ-
ence in the SNP ratio profiles could be found as deter-
mined by DNAcopy and GLAD package statistical
analysis (Fig 2). This result was confirmed by the quan-
titative real time PCR (qPCR) assays. The high level
expressing population was characterized by an average
copy number of 85 (median 85; range 50-145) whereas
27 egfr copies (median 27; range 10-83) could be shown
in the low level expressing cells. However, these gene
copy numbers could only be obtained immediately after
sorting due to the fact that during cell culture the copy
numbers increased (Fig 3). Therefore no stable popula-
tion showing an intermediate egfr copy number could
be cultured long term for continuative analyses. Addi-
tionally, comparison of gene copy numbers obtained by
FISH at different time points of cell culture revealed
that the MDA-MB-468 CD44
+/CD24
-/low populations
remain heterogeneous at the egfr locus (Fig. 3). The egfr
specific FISH signals in a population ranged from
diploid spots through multiple but still countable signals
up to huge clouds per cell. Despite this heterogeneity a
signal shift towards higher copy numbers could be seen
in respect to the culture period. During 92 days of cell
culture FISH analysis revealed a relative egfr copy num-
ber shift within the cell population from 7 to 16. This
was confirmed by qPCR where sorted cells started with
10 gene copies and ended up with 19 copies of the egfr
gene. This shift as well as the observed heterogeneity
may be based on asymmetric chromosomal segregation
within breakage fusion bridge cycles which brings about
cells with increased and decreased egfr gene copy num-
bers (Fig 4).
Cell cycle analysis revealed that cells with intermediate
egfr copy numbers went through mitosis slightly more
rapid than those with high copy numbers (Fig 5a). There-
fore, clonal effects mediated through growth advantage
of cells bearing higher egfr gene copy numbers being the
driving force in the development of a higher over all egfr
gene amplification might be less likely. In addition, in
metaphase spreads of MDA-MB-468 CD44
+/CD24
-/LOW
we found always no telomere on abnormal chromosomes
7p harbouring increased egfr copy numbers. The egfr
gene amplification was organized equal spaced in a lad-
der like structure and additionally no double minutes
have been detected (Fig 2). Therefore it could be
h y p o t h e z i s e dt h a tt h ei n c r e a s eo fg e n ec o p yn u m b e r s
might be a consequence of asymmetric chromosomal
segregation during recurrent breakage- fusion- bridge-
cycles. The heterogeneity in egfr gene copy numbers in
the MDA-MB-468 CD44
+/CD24
-/LOW EGFR expressors
which regained high amplification supports this assump-
tion (Fig. 3).
One of the main downstream effectors of the epider-
mal growth factor receptor (EGFR) is ras GTPase, an
integral molecule of the mitogen activated protein
kinase (MAPK) pathway which ends in the phosphoryla-
tion of extracellular signal regulated kinase (ERK). Acti-
vated ERKs translocate to the nucleus, where they
phosphorylate and regulate various transcription factors
leading to changes in gene expression. In particular,
ERK-mediated transcription can result in the upregula-
tion of EGFR ligands, such as EGF and TGFa, thus
creating an autocrine feedback loop that is critical for
Ras-mediated transformation and Raf-mediated gene
expression changes. Western blot analysis of the sub-
clones harbouring high and low egfr copy numbers
revealed an increased sensitivity of the high egfr gene
copy number subclone in response to EGF in as far the
phosphorylation of erk 1/2 is obviously higher (Fig. 5b
lane 3; for quantitative evaluation of western blot analy-
sis see, Additional file 1) than in the low copy number
subclone (Fig. 5b lane 6). Similar findings could be
shown for the activation of Akt, another important
downstream effector of the EGFR pathway. Taken
together, the high egfr copy number MDA-MB-468
CD44
+/CD24
-/LOW cells represent cancer cells with a
higher potential for survival, esp. at metastatic sites with
low growth factor concentrations as the host tissue. A
phenotype that can also be shown for cell lines with an
HER2 amplification and constitutive activation of HER2,
e.g. SKBR3 (Fig. 5A_lane 7-9) which displays high
motogenicity.
Discussion
The cell line MDA-MB-468 contains a subclone with a
stemness phenotype CD44
high/CD24
-/low expression
(Shown in Fig. 1, insert) [13,14]. Using standard culture
conditions this stable subclone does not show any phe-
notypically differences to the known MDA-MB-468.
Other properties like spheroidogenesis and tumorogen-
esis have not been tested so far. MDA-MB-468
CD44
high/CD24
-/low was sorted according to their
EGFR-expression in low and high expressing
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Page 4 of 10Figure 1 Isolation and re-analysis of low (B) and high (C) EGFR expressing subpopulations of the breast cancer cell line MDA-MB-468
CD44+/CD24 -/LOW (A). Isolation was done using a FACSVantage SE flow cytometer (Becton Dickinson). A primary gate (I; R3) based on
physical parameters (forward and side light scatter, FSC and SSC, respectively) was set to exclude debris and cell aggregates. Two additional
gates (II; R1, R2) were set discriminating clearly a high- from a low-level EGFR-expressing population. The analysis was performed using
CELLQUEST software (Becton Dickinson). Insert: Western blotting showed that used MDA-MB-468 clone was positive for CD44 and negative for
CD24 which is in agreement with the stemness cell line Hs578t. The same findings could be shown for the two isolated MDA-MB-468 subclones
with low high egfr copy numbers. Other used breast cancer cell lines like MCF-7, BT 20, BT 474 and SKBR 3 did not show this phenotype
irrespective of their EGFR expression.
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analyses (FISH, qPCR) confirmed a positive correlation
between EGFR expression and egfr gene copy numbers
indicating a direct effect on gene expression which is in
agreement with data from the literature for several can-
cer types basal like breast cancers included [1-3,19-21].
A dynamic regain of egfr gene copies was observed for
the low copy number subclone with time of cell culture.
After a period of 12 - 14 weeks the cells regained com-
pletely the high egfr copy numbers. It might be assumed
that this regain is caused by unequal segregation of
chromosomes 7p as the cell cycle velocity of low and
high copy number cells where determined nearly equal
(Fig. 4a) even with a slight growth advantage of the low
copy number cells. A possible mechanism of this pro-
c e s sm a yb ef o u n di nb r e a k a ge-fusion-bridge (BFB)-
cycles which can drive both, amplification [22,23] as
well as heterogeneity [24]. BFB-cycles are initiated by
chromosomal breakage of fragile sites distal to a selected
gene [25] and based upon asymmetric segregation at
mitosis. In consequence, the daughter cells will show up
with different gene copy numbers, one with an increased
copy number and the other with a diminished one. We
were previously able to show such a fragile site breaking
distal from the egfr locus [17] which might be the initia-
tion of BFB-cycles. After that, chromosome-ends remain
uncapped in the cells (Fig. 2) what gives some evidence
for the assumption that recurrent BFB-cycles further
promote amplifications and increase heterogeneity.
Additionally the egfr amplifications are equal spaced in a
ladder-like-structure (Fig. 2) and no double minutes
containing the egfr gene were detectable. Similar find-
ings could be shown in the human epidermoid cancer
cell line A431 (own results, data not shown). Both cell
Figure 2 Aberrations of chromosome 7 in MDA-MB-468CD44+/CD24 -/LOW. I) High resolution analysis by GeneChip Human Mapping 500
K arrays revealed a lot of aberrations occurring in MDA-MB-468 CD44+/CD24 -/LOW low as well high EGFR expressing cells. Based on DNAcopy
and GLAD statistical package analysis statistical significance for a difference in gene copy could only be estimated for the indicated region
containing the egfr gene on chromosome 7p. 2 II). Egfr FISH (green fluorescence) displays the egfr gene amplification based upon one
chromosome with multiple egfr gene copies (white arrow; a) in MDA-MB-468 CD44+/CD24 -/LOW metaphase spreads. The amplicon is equal-
spaced in a ladder like structure and the concerning telomere 7ptel (red fluorescence) is lost. Isochromosomes 7p are frequent findings (white
arrows; b).
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Page 6 of 10lines show an intrachromosomal egfr amplification with
the above mentioned findings but only A431 shows an
additional polysomy of chr7. Egfr gene amplification
reaches in both cell lines up to approx. 150 copies per
cell. Due to the polysomy in A431 the gene copies per
each chromosome do not reach the level which can be
found in MDA-MB-468. These copy numbers are much
higher than the ones which are seen in vivo and might
thus be due to cell culture conditions. Nevertheless the
structure of the egfr amplification in both cell lines is
pointing towards BFB cycles as the more likely underly-
ing mechanism for both the egfr amplification and the
observed heterogeneity in vitro [23], and conceivably
also in vivo.
In vivo, intratumoral genetic heterogeneity is not just
only a well-known characteristic of numerous cancers
but often confounds a precise diagnosis and leads to
therapy resistance of the cancer. In this context the effi-
ciency of antibodies targeting EGFR and small-molecule
inhibitors impairing EGFR tyrosine kinase activity have
to be discussed [26].
Nevertheless, we and other groups reported on the
existence of a field cancerization in the human breast
showing that the egfr aberrations were detected through-
out an individual lobule or duct within histologically
normal mammary epithelium with or without adjacent
carcinoma [17,27-30]. Such a model comprising stem/
progenitor cells and field cancerization could account
for phenotypic heterogeneity within individual
mammary tumors, since tumors would be composed of
tumor stem/progenitor cells as well as other more dif-
ferentiated progeny generated through aberrant differen-
tiation. In this context a supporting mechanism for
generating heterogeneity within clonal populations
might be specifically based on egfr amplifications in
stem/progenitor cells due to chromosomal breakage at a
f r a g i l es i t ea tc h r o m o s o m e7 p 1 5 .I tm i g h tb ec o n c l u d e d
from the data mentioned here that EGFR is tightly
involved in normal and cancer stem/progenitor cell sur-
vival, conceivably as self-renewal. Therefore, aberrations
of the egfr gene might be events that predispose cancer
cells or even its precursors for longevity and therapy
resistance.
The importance of the regain of egfr copy numbers is
also shown by our data on erk and akt phosphoryla-
tion. The main downstream effectors of EGFR are the
ras GTPase, initiating the phosphorylation of extracel-
lular signal regulated kinase (ERK) and PI3-kinase/akt.
Therefore, the expression level of EGFR constitutes the
sensitivity of the cancer cells to extracellular signalling.
This is rather diverse in the metastatic cascade a can-
cer cell has to traverse during progression of the dis-
ease and the settlement in low oxygen pressure tissues
as bone marrow and the brain. The resulting signals
regulate Ras-mediated transformation, Raf-mediated
gene expression changes, and akt/mTOR phosphorylat-
ing activity which are crucial for growth, survival, and
migration of cancer cells. Therefore, the regain of egfr
Figure 3 Increase of gene copy number of the egfr gene in the breast cancer cell line MDA-MB-468 CD44+/CD24 -/LOW during cell
culture. FISH analysis on interphase nuclei was done using an egfr specific probe counterstained with DAPI. The egfr gene amplification of a
low EGFR-expressing population (isolated by cell sorting) is increasing from the day of sorting (d = 0) to day 92 of culture. Quantification of in
situ hybridization was done by measuring fluorescence areas as single spots were not available in all cases. Here we give an example displaying
clearly this increase, as significant higher fluorescence intensities were obtained for cultured cells (T-Test: N1 and N2 = 200; P < 0.0001).
Histograms showing the distribution of amplification within the heterogeneous cell populations (green = d0; red = d92) were derived using R
and the akima package. Upward diagonals indicate new cells which were not present directly after sorting. Results were confirmed using qPCR.
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Page 7 of 10Figure 5 Functional analysis of MDA sublines. (A)Two parametric BrdU/Hoe33258 (Fl-IV) versus EtBr (Fl-III) fluorescence density plots of MDA-
MB-468 CD44+/CD24 -/LOW cells displayed clearly a higher proliferation rate of low (I) EGFR expressing cells (n = 3; mean R1/R2 = 32%/68%)
when compared with high (II) EGFR expressing cells (n = 3; mean R1/R2 = 41%/59%). (B) Western blot analysis of erk 1/2 (p44/p42 MAP -
Kinase), phospho-erk (Thr202/Tyr204), Akt and phospho-Akt (Ser473) in MDA-MB-468 CD44+/CD24 -/LOW high (lanes 1 - 3), MDA-MB-468 CD44
+/CD24 -/LOW low (lanes 4 - 6), and SK-BR-3 (lanes 7 - 9). Lanes 1, 4, and 7 represent protein expression of cells cultured in DMEM medium
supplemented with 5% FCS; proteins in lanes 2, 5, and 8 are from cells cultured under 0.1% FCS for 24 h; and proteins in lanes 3, 6, and 9 are
from cells stimulated with EGF (100 nM) for 30 minutes after FCS starvation for 24 h. For quantitative evaluation of western blot analysis see,
Additional file 1.
Figure 4 Scheme illustrating gene amplification and heterogeinity driven by asymmetric chromosomal segregation during BFB-cycles.
After an initial break uncapped chromosomes may fuse and form a bridge during anaphase. Breakage of this bridge will form two different
daughter cells one with amplification and one with deletion of the marker gene (digits indicate gene copy numbers). As chromosomes remain
uncapped recurrent cycles will promote amplification as well as heterogeneity of the cell population. By this cells with decreased, normal and
increased gene copy numbers persist simultaneously within the cell population.
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outgrowth of disseminated cancer cells at the meta-
static site [31].
Conclusions
A broad range of the egfr gene copy numbers leading to
different EGFR expression levels can be found simulta-
neously under normal cell culture conditions in the
breast cancer cell line MDA-MB-468 CD44+/CD24-/
LOW. Interestingly, by flow cytometry sorted lower
copy number clones showed regain of high copy num-
bers of egfr. This regain led to a heterogeneous popula-
tion with synchronous high-, intermediate- and near-
diploid copy number cells. The underlying mechanism
might include in part breakage fusion bridge (BFB)
cycles which can drive both, increase in gene copy num-
bers as well as genetic heterogeneity. We show here for
the first time a dynamic copy number regain which
might explain genetic heterogeneity and also might be
involved in regulation processes in cancer cells which
support survival and migration during cancer progres-
sion. Understanding of these mechanisms in vitro could
deepen the understanding of processes in vivo and
improve by this both diagnosis and therapy of the corre-
sponding cancers.
Additional file 1: Quantitative evaluation of western blot analysis.
This file contains the quantitative evaluation of western blot analysis
shown in Fig 5b.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
78-S1.PDF]
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